Biologics / Biotechnology

Flu virus
#Antivirals #Biologics / Biotechnology #Cidara #Influenza #Merck #Mergers and acquisitions

Merck acquires antivirals developer Cidara Therapeutics

Merck (MSD outside of the US and Canada) has acquired Cidara Therapeutics, a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, for approximately $9.2 billion.  Cidara’s lead candidate, CD388, consists of a small molecule neuraminidase inhibitor stably conjugated to a proprietary Fc fragment of a human antibody designed to prevent influenza… Read More

#Business & Investment #News

European biotech
#Biologics / Biotechnology #Biotech #Europe #European Commission #European Union

Is the European Biotech Act a one-shot solution for the biotech sector?

For European Biotech Week, Diana Turner and Dr Claire Skentelbery, Director General, EuropaBio, examine the potential impact of the European Biotech Act. The European Biotech Act was first introduced by Ursula von der Leyen in 2024 in her paper ‘Europe’s Choice: Political Guidelines For The Next European Commission 2024−2029’. She… Read More

#Exclusive Content #Trends & Analysis

#BioInnovation Institute #Biologics / Biotechnology #Biotech hubs #Drug discovery #Funding #Investment #Life sciences #Market reporting #Start-ups #United States

New podcast: Global epicentres of drug discovery innovation

This is the latest episode of the free DDW narrated podcast, titled “Where are the global epicentres of drug discovery innovation?”, which covers two articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: Where are the hottest drug discovery hubs in the… Read More

#News

#Biologics / Biotechnology #Cell therapy #CNS #Financing #Kenai Therapeutics #Neurology #Parkinson's

$82m investment in cell therapies for neurological diseases

Biotechnology company Kenai Therapeutics has raised $82 million in a Series A financing co-led by Alaska Permanent Fund Corporation, Cure Ventures and The Column Group. Kenai Therapeutics previously raised seed funding under the name Ryne Bio. “We are grateful for the support of a syndicate of leading life science investors… Read More

#Business & Investment #News

#Autoimmune disease #Biologics / Biotechnology #COUR Pharmaceuticals #Financing #Investment

$105 million raised to support therapies for autoimmune diseases

COUR Pharmaceuticals has secured $105 million in a Series A investment round co-led by Lumira Ventures and Alpha Wave Ventures. The funds will be used to support the advancement of COUR’s myasthenia gravis (MG) and type 1 diabetes (T1D) product candidates into Phase IIa clinical trials. The Roche Venture Fund,… Read More

#Business & Investment #News

European map
#Advanced Therapies Europe #Biologics / Biotechnology #Cancer immunotherapy #CAR-T #Cell and gene therapy #Cell therapy #Collaboration #Europe #Immuno-oncology #Market reporting #Oncology #Start-ups

New podcast: Why is Europe a drug discovery epicentre?

This is the latest episode of the free DDW narrated podcast, titled “Revolutionary technology for drug discovery and development” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: European drug discovery and development success stories,… Read More

#News

Lisbon skyline
#Antibodies #Antibody drug conjugate (ADC) #Biochemistry #Biologics #Biologics / Biotechnology #Bispecific Antibodies #Combination therapy #Engineered antibodies #PEGS Europe 2023

What to expect from PEGS Europe 2023: Day 1

Ahead of protein and antibody engineering conference PEGS Europe 2023 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. On Day 1, Tuesday 14 November 2023, the tracks include: Display of biologics, antibody-based cancer therapies, safety and efficacy of bispecific… Read More

#Exclusive Content

FDA headquarters
#Biologics / Biotechnology #FDA #Rare disease #Regulatory

FDA pilot programme to boost rare disease therapies

The US Food and Drug Administration (FDA) has announced a pilot programme with the aim of accelerating the development of novel drug and biological products for rare diseases. The agency is inviting a limited number of sponsors to participate in the programme, which allows for more frequent communication with FDA… Read More

#News #Regulatory

Biologics research
#Biologics #Biologics / Biotechnology #Drug discovery #Infographic

Characterisation of candidates during biologic development

Download the new Infographic from NanoTemper: ‘Stability assessment of biologics during early development workflows‘. During early development of biologics, there are a large number of attributes researchers evaluate, but some of the most common centre around stability – asking if a biologic is well-folded, active and pure… Read More

#News

#Biologics #Biologics / Biotechnology #Drug discovery #Infographic

Stability assessment of biologics during early development workflows

During early development of biologics, there are a large number of attributes researchers evaluate, but some of the most common centre around stability – asking if a biologic is well-folded, active and pure in its buffer, and whether it remains that way over time. Biophysical characterisations are valuable for providing… Read More

#Intelligence #Resources

#Assay #Biologics / Biotechnology #Biopharma #Diversity #DNA #Drug development #Drug discovery #Gene sequencing #Ingredients / APIs / Fine chemicals #Synthetic biology #Women in Discovery #Women in STEM

New podcast: Overcoming different barriers in drug discovery

This is the latest episode of the free DDW narrated podcast, “Overcoming different barriers in drug discovery”, which covers three articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “Addressing the challenge of salt forms in drug discovery”, “… Read More

#News

Great British Pounds, Investment
#ABPI #BioIndustry Association #Biologics / Biotechnology #Clarivate #Financing #Investment #UK

UK biotech financing up 29% on last quarter

The second quarter of 2023 has seen steady growth in financing activity for the UK’s life sciences sector, according to new data released by the BioIndustry Association (BIA) and Clarivate. The positive news comes soon after industry figures welcomed recent announcements to unlock new sources of capital in the City… Read More

#Business & Investment #News

#Biologics / Biotechnology #Cytiva #Mergers and acquisitions #Pall Life Sciences

Cytiva and Pall Life Sciences complete integration

Cytiva and the life sciences business of Pall Corporation have completed their integration and are now united as one business under the Cytiva brand. In January 2023, the life sciences business of Pall separated from Pall Corporation. Pall’s biotech portfolio is now a product family in Cytiva’s bioprocess business. The… Read More

#Business & Investment #News

Map of the United States
#Biologics / Biotechnology #Biotech hubs #Life sciences #Market reporting #United States

Where are the hottest drug discovery hubs in the US?

Listen to this article on the DDW Podcast: DDW's Megan Thomas takes a snapshot of the US biotech market and some of the ongoing research coming out of the US. In 2021, Savills put together a report on the regional hubs attracting science/pharma investment1. The report notes that the focus on science… Read More

#Exclusive Content #Market Reports

Seed fund
#Biologics / Biotechnology #Funding #Investment #SolasCure #Wound care

SolasCure secures £10.9m funding to develop Aurase Wound Gel

Biotechnology company SolasCure has completed its £10.9m ($13.3m) Series B investment round. The funding round was led by Seneca Partners and also included BRAIN Biotech, EVA Pharma, Jonathan Milner, and Wealth Club. SolasCure's first investigational product, Aurase Wound Gel, a hydrogel containing an enzyme cloned from medical maggots which aims… Read More

#Business & Investment #News

Bone marrow transplant operation
#Biologics / Biotechnology #Cell therapy #FDA #Graft vs Host Disease #Mesoblast #Transplant

“Off-the-shelf” cellular medicine resubmitted to the FDA

Mesoblast has resubmitted its biologics license application (BLA) to the US Food and Drug Administration (FDA) for approval of remestemcel-L in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD).  Survival outcomes have not improved over the past two decades for the most severe forms of SR-… Read More

#News #Regulatory